Introduction
The receptor tyrosine kinase vascular endothelial growth factor receptor 3 (VEGFR-3, previously denoted fms-like tyrosine kinase-4; Flt-4) is essential for the development of the blood and lymphatic vasculature. Inactivation of the VEGFR-3 gene in mouse embryos leads to a disturbed vascular development resulting in an irregular vessel pattern and a reduced cross-sectional area of large vessels. The embryos die at embryonic day 9.5 due to fl uid accumulation in the pericardial cavity and cardiovascular failure (3) .
In adult tissues, VEGFR-3 is expressed primarily on lymphatic endothelial cells (34) and appears to exert its major functions within this system. Thus, inactivating missense point mutations in one VEGFR3 allele lead to chronic lymphedema (13) . Further, overexpression of a soluble VEGFR-3 in mice leads to regression of lymph vessels and features characteristic of lymphedema, without any apparent effects on the blood vasculature (18). In several tumor models, overexpression of the VEGFR-3 ligand VEGF-C increases lymphangiogenesis and promotes spread of metastases (15, 22, 29) . The same effect is achieved by over expression of VEGF-D, another VEGFR-3 ligand (30) .
VEGFR-3 is to some extent expressed also on quiescent vascular endothelial cells, primarily in fenestrated capillaries (17, 27, 34) . Very low levels can be occasionally detected in the blood vascular endothelium of wound granulation tissue, and in vessels stimulated with VEGFs (5, 35) . Further, the endothelium of angiogenic blood vessels of several tumors express VEGFR-3 (26, 31, 35) . These results suggest that VEGFR-3 could be involved in aspects of angiogenesis in adults.
The VEGFR-3 is similar in the overall structure to the VEGFR-1 and VEGFR-2 (24); the extracellular, ligand-binding domain is composed of seven immunoglobulin (Ig)-like folds and the intracellular domain is characterized by an interrupted tyrosine kinase domain. In contrast to the other VEGF receptors, the VEGFR-3 extracellular domain is cleaved within the 5th Ig-homology domain; the resulting two polypeptides are held together by a disulfi de bridge (25) . In humans, but not in mice,
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Cell lines and cell culture Porcine aorta endothelial (PAE) cells, stably overexpressing VEGFR-3 or VEGFR-2 were maintained in F12/10% fetal calf serum (FCS). Human 293T cells were used for transient expression of VEGFR-3 and were maintained in DMEM/10% FCS. Primary lymphatic endothelial cells (LECs) were separated from human dermal microvascular endothelial cells as previously described (19) using antibodies against podoplanin. The cells were cultured on gelatin-coated plastic in endothelial basal medium (EBM, CC-3121, Clonetics, Walkersville, Maryland) supplemented with 5% FCS, 30 µg/ml endothelial growth culture supplement (ECGS, E-7060, Sigma, St Louis, Missouri), 10 ng/ml EGF and 10 ng/ml VEGF-C (Thr103-Ile225).
Generation of mutated VEGFR-3 VEGFR-3 tyrosine mutants were generated by the GeneEditor in vitro Site-Directed Mutagenesis kit (Promega) using oligonucleotides in which one nucleotide change in the tyrosine encoding sequence was introduced, resulting in Tyr-> Phe amino acid change in the protein sequence.
VEGFR-3 kinase dead (R3-KD; R1041P and R978G) mutants were generated as above using oligonucleotides which introduced desired nucleotide changes in the VEGFR-3 kinase-domain encoding sequence. The R1041P represents a mutation found in lympedema (14) while in the K879G mutant the ATP-binding Lys has been changed into Gly. Both mutant proteins were found to be kinase-inactive when expressed in 293T-cells (14) .
Transient transfections
Vectors (pcDNA3.1/Zeo, Invitrogen AB, Lidingö, Sweden) encoding wild type and mutant VEGFR-3 were transfected into human 293T cells using the calcium phosphate method. In brief, 6 x10 6 cells in 10 cm Petri dishes were treated with 25 µM chloroquine for 1.5 h. Vector cDNA (4-Immunocomplex kinase assay and SDS-PAGE Immunocomplex kinase assay and SDS-PAGE The cells were starved over night in serum-free medium supplemented with 0.1% bovine serum albumin, and treated for 8 min with or without VEGF or VEGF-C using 50 ng/ml, washed in Trisbuffered saline (TBS)/100 µM Na 3 VO 4 . on ice. The cells were lysed in ice-cold NP40 lysis buffer (1% Nonidet P40, 20 mM Hepes, pH 7.5, 150 mM NaCl, 10% glycerol, 2.5 mM EDTA, 10 IEu aprotinin/ ml, 1 mM PMSF, and 100 µm Na 3 VO 4 ). An aliquot of the cell lysate was saved for control blotting. 
Immunoblotting Immunoblotting
Samples were prepared essentially as described above but without the kinase reaction, separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane. The membranes were incubated with indicated primary antibodies and subsequently, with HRP-conjugated secondary antibodies. Immunoreactive sites were visualized using an enhanced chemiluminescence detection system (Amersham Biosciences, Uppsala, Sweden).
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Phosphopeptide mapping Phosphopeptide mapping
The detailed procedure has been described previously (1, 32 One hundred and forty µl pH 1.9 buffer (2.2% formic acid and 7.8% acetic acid in H 2 0) was added and any particles were precipitated by centrifugation. One hundred and eighty µl of the supernatant was lyophilized and dissolved in 7 µl pH 1.9 buffer. The samples were centrifuged and 6 µl of each sample was gently dried onto a cellulose covered thin-layer chromatography glass plate (#1.05716, Merck, Darmstadt, Germany) as a spot of about 5 mm in diameter, localized 5 cm from the left side and 3 cm from the bottom of the plate. The peptides were separated by electrophoresis (x-axis) using pH 1.9 buffer and the plate was dried. Separation in the second dimension (y-axis) was performed by ascending chromatography using isobutyric acid buffer (62.5% isobutyric acid, 1.9% n-butanol, 4.8% pyridine, 2.9% acetic acid in H 2 O) over night. The plate was dried and the peptides with incorporated 32 P were detected by the BioImager. Using the resulting phosphopetide map for localization, cellulose containing peptide spots of interest were scraped off the chromatography plate. The peptides were extracted by pH 1.9 buffer, lyophilized, and used for Edman degradation or phosphoaminoacid analysis.
Edman degradation and radio amino acid sequencing Edman degradation and radio amino acid sequencing For Edman degradation, phosphopeptides were coupled to sequelon-AA membranes (Millipore, Sundbyberg, Sweden) and sequenced using a Gas Phase sequencer (Applied Biosystems, Foster City, California). The fractions were spotted onto thin-layer chromatography plates, detected by BioImager Phospho-amino acid analysis Phospho-amino acid analysis
The samples extracted from the thin-layer plates were hydrolyzed in 6 M HCl at 110°C and lyophilized, dissolved in H 2 O and lyophilized again. The samples were dissolved in 7 µl pH 1.9 buffer supplemented with non-radioactive phosphorylated serine, threonine and tyrosine as markers and spotted onto a thinlayer chromatography plate. Electrophoresis using fi rst the pH 1.9 buffer (x-axis) and subsequently the pH 3.5 buffer (acetic acid 5% and pyridine 0.5% in H 2 O; y-axis) provided two-dimensional separation of the hydrolyzed amino acid residues. The dried plates were sprayed with ninhydrin for detection of the marker phospho-amino acid residues. The plate was dried and the incorporated 32 P was visualized using the BioImager. By overlaying the resulting image with the ninhydrin pattern of the marker amino acids, the identity of the amino acid residues with incorporated 32 P was determined.
Results
Phosphorylation of VEGFR-3. Phosphorylation of VEGFR-3.
The intracellular domain of the long form of VEGFR-3 contains 16 tyrosine residues. Of these, six tyrosine residues are located in the carboxy-terminal tail (denoted Y1230, Y1231, Y1265, Y1333, Y1337 and Y1363; Fig.1 ). Trypsin digestion of the VEGFR-3 intracellular domain results in the generation of up to 17 tyrosine-containing peptides, of which four are derived from the carboxyterminal tail (Table 1) . We wished to determine which of the carboxy-terminal tyrosine residues that could serve as potential phosphorylation sites. Stimulation of PAE cells expressing VEGFR-3
with VEGF-C, resulted in strong induction of VEGFR-3 phosphorylation, as estimated in an in vitro immunocomplex kinase assay ( Fig. 2A) . Trypsin-digested peptides of the receptor were separated by electrophoresis according to the charge/mass ratio (x-axis) and by liquid chromatography according to hydrophobicity (y-axis), creating a phosphopeptide map. In this analysis, a corresponding increase in phosphorylation was detected in an analysis of trypsin-generated peptides from the ligand-stimulated VEGFR-3 (Fig. 2B ).
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Position of phosphorylated residues Position of phosphorylated residues
Peptides giving reproducible spots in the phosphopeptide maps were extracted, hydrolyzed in hydrochloric acid and separated by two-dimensional electrophoresis on thin-layer plates. Unlabeled phosphoamino acid residues served as references (indicated by circles in the insets in Fig. 2C ).
Peptides displaying tyrosine phosphorylation (encircled by in Fig. 2B ) were subjected to Edman degradation. Chemical identifi cation of amino acid residues was not feasible due to the minute amounts of protein in the assay. Instead, the material in each cycle was spotted individually on thin-layer chromatography plates and the 32 P-content in each fraction was quantifi ed after exposure and detection using a BioImager. The positions of the radioactive peaks were the basis for tentative identifi cation of a tryptic peptide containing a tyrosine residue in the corresponding position. Peptides from some distinct spots displayed identical radiosequences (spots denoted c in Fig. 2 ). This may be due to serine phosphorylation of the corresponding peptide, which contains fi ve serine residues. Serine phosphorylation was indeed detected in the leftmost spot (data not shown). The predicted change in the phosphopeptide map position due to such a modifi cation is in compliance with the observed positions.
An alterative explanation to multiple spots is partial oxidation of cysteine residues with consequences for the charge and thereby the migration position of the peptide.
Analyses of VEGFR-3 tyrosine to phenylalanine mutants Analyses of VEGFR-3 tyrosine to phenylalanine mutants
The above results indicated that all tyrosine residues in the carboxy-terminal tail, with the possible exception of Y1333, were phosphorylated. To further exploit these fi ndings, we created six receptors variants, point mutated in the carboxy-terminal tail, each with a single amino acid exchange from tyrosine to phenylalanine. These receptors were denoted Y1230F-R3, Y1231F-R3, Y1265F-R3, Y1333F-R3, Y1337F-R3 and Y1363F-R3. Phosphopeptide mapping of the mutant receptors transiently expressed in 293 cells, confi rmed the preliminary identifi cation of the phosphopeptides (Fig. 3) . In the phosphopeptide map of Y1265F-R3 one spot was lost whereas the map of Y1337F-R3
showed loss of three spots (Figure 3 ). The corresponding spots in the Y1333F-R3 map were shifted 10 in the y-direction indicating increased hydrophobicity, in agreement with the expected change as a result of the exchange of tyrosine for phenylalanine. The Y1337 residue was still phosphorylated in this peptide. The peptides containing Y1230/Y1231 and Y1363 were not fully separated, but analysis of this region in the phosphopeptide map (boxed in Fig. 3A ) by scanning densitometry confi rmed that loss of tyrosine phosphorylation as a consequence of the different mutations resulted in the expected phosphopeptide pattern (Fig. 3H ).
VEGFR-2 and VEGFR-3 heterodimerization in primary cells. VEGFR-2 and VEGFR-3 heterodimerization in primary cells.
We wished to verify that the phosphorylation pattern of VEGFR-3 overexpressed in PAE or 293 cells mimicked that of the endogenously expressed VEGFR-3 in primary lymphatic endothelial cells (LECs). Fig. 4 shows that the phosphopeptide map of LEC-derived VEGFR-3 was essentially indistinguishable from that of the overexpressed recombinant receptor, confi rming the relevance of our approach. Minor differences in migration positions of a collection of spots in the right margin were anticipated, as there had been some variations in this region of the TLC plate also between repeated maps of VEGFR-3 overexpressed in the 293 cells.
The immunocomplex kinase assay of VEGFR-3 immunoprecipitated from VEGF-C-stimulated
LECs demonstrated that a phosphorylated protein of 220 kDa was co-immunoprecipitated by the VEGFR-3-specifi c antibodies. We hypothesized that this component could correspond to VEGFR-
This was confi rmed by phosphopeptide mapping (data not shown). To investigate under which
conditions the association between VEGFR-2 and VEGFR-3 occurred, LECs were treated with VEGF, specifi c for VEGFR-2, or VEGF-C, a ligand for both receptors. Immunoprecipitation with antibodies specifi c for the respective receptors, followed by immunocomplex kinase assay, demonstrated that the association was evident only after stimulation with VEGF-C (Fig. 5A) . The specifi city of the antibodies was confi rmed by immunoprecipitation and blotting of cell lysates derived from PAE cells overexpressing either VEGFR-2 or VEGFR-3 (Fig. 5B) . The different levels of kinase activity and the different properties of the antisera used precluded a determination of the relative stoichiometry of heterodimers versus homodimers in the VEGF-C-treated LECs.
Distinct pattern of phosphorylation of VEGFR-3 in the heterodimeric confi guration Distinct pattern of phosphorylation of VEGFR-3 in the heterodimeric confi guration
To examine if VEGFR-3 was phosphorylated similarly in the homodimeric and the heterodimeric confi guration, a kinase-dead mutant VEGFR-3 in which the ATP-binding lysine is mutated (R1041P;
here denoted R3-KD) was expressed alone or in combination with VEGFR-2 or VEGFR-3 in 293 cells. The V5-tagged R3-KD was specifi cally recognized by anti-V5 antibodies, ensuring that the analysis was focused on R3-KD dimerized with kinase active VEGFR-2 or VEGFR-3. In this set-up, phosphorylation of R3-KD was dependent on the co-expressed kinase active receptors. As shown in Fig. 6 , wt-VEGFR-3-mediated phosphorylation of R3-KD resulted in a phosphopeptide map very similar to the previous VEGFR-3 maps (see Fig. 1 ). In contrast, the map of R3-KD phosphorylated by VEGFR-2 lacked spots corresponding to peptides containing tyrosine residues Y1337 and Y1363.
Repeating the analysis using another kinase inactive VEGFR-3 (K879G; (14)) gave identical results (data not shown).
Discussion
Tyrosine phosphorylation sites in receptor tyrosine kinases regulate both kinase activity and interaction with signal transduction molecules. Thus, identifi cation of these sites is of fundamental importance in understanding the signaling of a specifi c receptor. We show that fi ve (Y1230, Y1231, Y1265, Y1337 and Y1363) of the six tyrosine residues in the C-terminal tail of VEGFR-3 are potential phosphorylation sites. The role of most of these sites in signal transduction downstream of VEGFR-3 remains to be determined. Y1337 is required for association of the Shc/Grb2 complex to VEGFR-3 (6) and this interaction has been linked to the transforming capacity of the receptor overexpressed in fi broblasts. In accordance, the short form of the VEGFR-3 that lacks the tyrosines Y1333, Y1337 and Y1363, is unable to mediate fi broblast transformation.
Our preliminary results suggest that the tyrosine residues 1063 and 1068 in the second kinase domain become phosphorylated upon receptor activation (data not shown). The positions of these 12 sites corresponds to those previously implicated in positive regulation of tyrosine kinase activity, e.g. Y1054 and Y1059 in VEGFR-2 (20) . We therefore suggest that Y1063 and Y1068 in VEGFR-3 serve a positive regulatory role in the activation of the VEGFR-3 kinase. Of the remaining tyrosine residues in the intracellular domain of VEGFR-3, fi ve are located in the fi rst and second parts of the kinase domain, and three are located in the juxtamembrane domain (Y812, Y830 and Y833). Tyrosine residues at positions conserved relative to Y812 are found both in VEGFR-1 (Y794) and VEGFR-2 (Y801) (10). All three VEGFR-3 juxtamembrane tyrosine residues are contained within the same tryptic peptide. Edman degradation of this peptide has not allowed an unambiguous conclusion on the phosphorylation of these tyrosine residues.
The kinase insert domain plays an important role in signal transduction by the PDGF receptors. This sequence is of varying length in different the receptor tyrosine kinases and it is usually not conserved between otherwise related receptors, such as the PDGF α-and β-receptors (2), which has prompted the suggestion that the kinase insert is important in receptor type-specifi c signaling. It is therefore interesting that neither the VEGFR-1 nor the VEGFR-3 kinase insert contain any tyrosine residues.
In contrast, the VEGFR-2 kinase insert contains three tyrosine residues of which at least one is a phosphorylation site (20) .
Our analysis of VEGFR-3 tyrosine phosphorylation in primary lymphatic endothelial cells allowed the following conclusions: 1) The phosphorylation pattern of VEGFR-3 was faithfully reproduced between the receptor overexpressing cells and primary LECs; 2) In these primary cells, VEGF-C, but not VEGF, treatment induced formation of VEGFR-2 and VEGFR-3 heterodimers; 3) VEGFR-3 phosphorylation site usage was altered in the heterodimeric confi guration. Thus, the two most Cterminal tyrosine residues in VEGFR-3 are substrates only for the VEGFR-3. VEGFR-3 in adult blood vessels and at least some lymphatic endothelia occurs in areas with VEGFR-2 expression (28, 34), indicating that VEGFR-2/VEGFR-3 heterodimers may form in vivo. Interestingly, recent data suggest that VEGFR-3 modulates the sensitivity to VEGFR-2 signaling to promote vascular integrity in blood vascular endothelial cells co-expressing the two receptors (16, 21) . It is possible that such a cross-talk between the receptors is dependent on heterodimerization. Table 1 Predicted tyrosine-containing peptides 
